Background: Conventional chemotherapy is commonly used to treat non-small cell lung cancer (NSCLC) however it increases therapeutic resistance. In contrast, metronomic chemotherapy (MET) is based on frequent drug administration at lower doses, resulting in inhibition of neovascularization and induction of tumor dormancy. This study aims to evaluate the inhibitory effects, adverse events, and potential mechanisms of MET Vinorelbine (NVB) combined with an angiogenesis inhibitor (Endostar).
Methods: Circulating endothelial progenitor cells (CEPs), apoptosis rate, expression of CD31, vascular endothelial growth factor (VEGF), hypoxia inducible factor-1 (HIF-1α) were determined using flow cytometry, western blot analysis, immunofluorescence staining and Enzyme-linked immunosorbent assay (ELISA) analysis. And some animals were also observed using micro fluorine-18-deoxyglucose PET/computed tomography (F-FDG PET/CT) to identify changes by comparing SUVmax values. In addition, white blood cell (WBC) counts and H&E-stained sections of liver, lungs, kidney, and heart were performed in order to monitor toxicity assessments.
Results: We found that treatment with MET NVB + Endo was most effective in inhibiting tumor growth, decreasing expression of CD31, VEGF, HIF-1α, and CEPs, and reducing side effects, inducing apoptosis, such as expression of Bcl-2, Bax and caspase-3. Administration with a maximum tolerated dose of NVB combined with Endostar (MTD NVB + Endo) demonstrated similar anti-tumor effects, including changes in glucose metabolism with micro fluorine-18-deoxyglucose PET/computed tomography (F-FDG PET/CT) imaging, however angiogenesis was not inhibited. Compared with either agent alone, the combination of drugs resulted in better anti-tumor effects.
Conclusion: These results indicated that MET NVB combined with Endo significantly enhanced anti-tumor and anti-angiogenic responses without overt toxicity in a xenograft model of human lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180630 | PMC |
| http://dx.doi.org/10.1186/s12885-018-4738-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of Vocal and Pulmonary Health Through Acoustic Analysis of Voice and Respiratory Measurements in People With Long COVID-19 Symptoms.
J Voice
December 2024
Department of Music, Faculty of Human Ecology, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia. Electronic address:
Background/objectives: The coronavirus disease (COVID-19) pandemic has significantly impacted global health, with Malaysia reporting over 5 million cases as of May 2024. While symptoms like fatigue and breathlessness are commonly reported among COVID-19 patients, limited research exists on the vocal and pulmonary conditions of individuals with long COVID symptoms. This study aims to assess vocal impairments and pulmonary function differences between long COVID patients and healthy controls, addressing gaps in understanding how long COVID affects vocal and respiratory health.
View Article and Find Full Text PDFIntegrating clinical and image-based parameters for prediction of early post-prostatectomy incontinence recovery: simplified nomogram approach.
BMC Cancer
October 2024
Division of Urology, Department of Surgery, Linkou Branch, Chang Gung Memorial Hospital, No.5, Fusing St., Gueishan Dist, Taoyuan, Taiwan.
Article Synopsis
- This study developed a new model that merges clinical data and imaging results to more accurately predict early recovery from urinary incontinence following robotic-assisted radical prostatectomy (RARP).
- Researchers analyzed data from 293 patients, finding that 47.6% were pad-free within a month, with over 90% achieving continence by six months.
- Significant predictors for recovery included BMI, nerve-sparing techniques, and bladder neck positioning, leading to the creation of a nomogram to help clinicians manage patient care and alleviate concerns.
A novel pelvis-prostate model BPPP predicts immediate urinary continence after Retzius-sparing robotic-assisted laparoscopic radical prostatectomy.
Sci Rep
August 2024
Department of Urology, Nanjing Drum Tower Hospital, Affiliated Medical College of Nanjing University, Nanjing, 210008, China.
This study aimed to construct a novel pelvis-prostate model BPPP which consists of body mass index (BMI), prostate volume (PV), pelvic cavity index (PCI) and prostate-muscle index (PMI) to predict the immediate urinary continence after Retzius-sparing robot assisted laparoscopic radical prostatectomy (RS-RARP). The perioperative data of patients with prostate cancer who underwent RS-RARP in the department of urology of Nanjing Drum Tower Hospital from June 2018 to June 2022 were retrospectively analyzed. 280 patients were eligible for this study in total.
View Article and Find Full Text PDFMetronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.
Nat Med
September 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- A phase 2 clinical trial explored the efficacy of metronomic chemotherapy combined with PD-1 blockade in patients with metastatic HER2-negative breast cancer, comparing it to conventional chemotherapy.
- The study found that the metronomic VEX regimen (which includes vinorelbine, cyclophosphamide, and capecitabine) and conventional cisplatin both had high disease control rates (DCR) of around 69.7% and 73.7%, respectively, with VEX showing the longest median progression-free survival of 6.6 months.
- Overall, all treatment regimens were well tolerated, with common side effects including nausea and neutropenia, and results suggest that metronomic VEX with PD
State-of-the-art diagnosis of autoimmune blistering diseases.
Front Immunol
June 2024
Department of Dermatology, Allergology and Venerology, University of Lübeck, Lübeck, Germany.
Article Synopsis
- - Autoimmune blistering disorders (AIBDs) include various conditions such as pemphigus and pemphigoid, characterized by blisters and skin lesions that can have diverse appearances, making accurate diagnosis essential for treatment and prognosis.
- - Diagnosis typically combines clinical evaluation with the detection of specific autoantibodies, utilizing tests like enzyme-linked immunosorbent assay (ELISA) and direct immunofluorescence microscopy (IFM), which is considered the gold standard.
- - Recent advancements in molecular identification of target antigens have led to new diagnostic methods and treatment approaches, enhancing the ability to detect specific antibodies related to various AIBDs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!